An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 496-499

  Pawinski, A ^a,b   Van Oosterom, A T ^a,b   De Wit, R ^c   Fossa S ^d   Croles, J ^e   Svedberg, A ^f   Lentz, M A ^a   De Mulder, P H M ^g  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e JEROEN BOSCH HOSPITAL   (Netherlands)

^f PFIZER INC   (United States)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

advanced renal cell carcinoma; linomide; phase II study

Indexed keywords

ROQUINIMEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INFLUENZA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0031106193     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89028-4     Document Type: Article

References (17)

1. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2 in advanced renal carcinoma. Treatment results and survival in 159 patients with long term follow-up. J Clin Oncol. 11:1993;1368-1375.
2. Atkins MB, Sparano J, Fisher RI, et al. Randomised phase II trial of high dose Interleukin-2 either alone or in combination with Interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 11:1993;661-667.
3. Nived O, Sturfelt G, Nilsson B, et al. Clinical pilot study of Roquinimex (Linomide) in patients with autoimmune disease. Int J Immunother. 2:1994;49-59.
4. Vukanovic J, Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by antiangiogenic agent Linomide. Cancer Res. 55:1995;3517-3520.
5. Bergh J, Nilsson S, Ahlbom H, et al. A phase II study with Roquinimex (Linomide) on patients with metastatic renal cell carcinoma. Ann Oncol. 1:1992;151. (Suppl.).
6. Who Handbook for Reporting Results of Cancer Treatment. WHO Offset Publications No. 48. 1979;. Geneva.
7. Vukanovic J, Passaniti A, Hirata T, Traystman J, Hartley-Asp B, Isaacs JT. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 53:1993;1833-1837.
8. Joseph I, Vukanovic J, Isaacs JT. Antiangiogenic treatment with Linomide as chemoprevention for prostate, seminal vesicle and breast carcinogenesis in rodents. Cancer Res. 56:1993;3404-3408.
9. Kalland T. The effects of the immunomodulator LS2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 46:1986;3018-3022.
10. Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol. 144:1990;4472-4476.
11. Bengtsson M, Simonssonn B, Carlsson K, et al. Stimulation of NK cell, T cell and monocyte functions by the novel immuno-modulator Linomide after autologous bone marrow transplantation. Transplantation. 53:1992;882-888.
12. Gasparini G. Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies. Eur J Cancer. 32A:1996;2379-2385.
13. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 32A:1996;2534-2539.
14. Castronovo V, Belotti D. TNP-470: mechanism of action and early clinical development. Eur J Cancer. 32A:1996;2520-2527.
15. Dirix LY, Vermeulen PB, Fierens H, De Schepper B, Corthouts B, Van Oosterom A. A long-term results of continuous treatment with recombinant interferon-alfa in patients with metastatic carcinoid tumours - an antiangiogenic effect? Anticancer Drugs. 7:1996;175-181.
16. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer. 32A:1996;2528-2533.
17. Teicher BA, Emi Y, Kakeji Y, Northey D. TNP-47 (minocycline) cytotoxic therapy: a systems approach to cancer therapy. Eur J Cancer. 32A:1996;2461-2466.